NO313685B1 - Oral rehydreringslösning - Google Patents

Oral rehydreringslösning Download PDF

Info

Publication number: NO313685B1
Authority: NO; Norway
Prior art keywords: difficile; diarrhea; fos; colitis; solution
Prior art date: 1995-04-05

Application number

NO19974490A

Other languages

English (en)

Norwegian (no)

Other versions

NO974490D0 (no

NO974490L (no

Inventor

Keith Allen Garleb

Brian Warren Wolf

Jonathan Allan Meulbroek

Keith Brian Wheeler

Shelia Martinson Campbell

Joseph Edward Walton

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-05

Filing date

1997-09-29

Publication date

2002-11-18

1995-04-05 Priority claimed from US08/417,411 external-priority patent/US5733579A/en

1995-04-05 Priority claimed from US08/417,413 external-priority patent/US5688777A/en

1997-09-29 Application filed by Abbott Lab filed Critical Abbott Lab

1997-09-29 Publication of NO974490D0 publication Critical patent/NO974490D0/no

1997-09-29 Publication of NO974490L publication Critical patent/NO974490L/no

2002-11-18 Publication of NO313685B1 publication Critical patent/NO313685B1/no

Links

239000000310 rehydration solution Substances 0.000 title claims abstract description 17
229920001542 oligosaccharide Polymers 0.000 claims abstract description 18
150000002482 oligosaccharides Chemical class 0.000 claims abstract description 18
239000000243 solution Substances 0.000 claims description 14
210000001035 gastrointestinal tract Anatomy 0.000 claims description 12
241000282414 Homo sapiens Species 0.000 claims description 9
LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 claims description 6
LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 claims description 6
SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 claims description 6
HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 6
239000011734 sodium Substances 0.000 claims description 6
229910052708 sodium Inorganic materials 0.000 claims description 6
JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 claims description 5
JVZHSOSUTPAVII-UHFFFAOYSA-N Xylotetraose Natural products OCC(OC1OCC(OC2OCC(OC3OCC(O)C(O)C3O)C(O)C2O)C(O)C1O)C(O)C(O)C=O JVZHSOSUTPAVII-UHFFFAOYSA-N 0.000 claims description 5
JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 claims description 5
FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
229940107187 fructooligosaccharide Drugs 0.000 claims description 5
FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 claims description 5
ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 claims description 5
230000029087 digestion Effects 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
VAWYEUIPHLMNNF-OESPXIITSA-N 1-kestose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VAWYEUIPHLMNNF-OESPXIITSA-N 0.000 claims 1
GIUOHBJZYJAZNP-DVZCMHTBSA-N 1-kestose Natural products OC[C@@H]1O[C@](CO)(OC[C@]2(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GIUOHBJZYJAZNP-DVZCMHTBSA-N 0.000 claims 1
VAWYEUIPHLMNNF-UHFFFAOYSA-N kestotriose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 VAWYEUIPHLMNNF-UHFFFAOYSA-N 0.000 claims 1
241000193163 Clostridioides difficile Species 0.000 abstract description 95
238000011282 treatment Methods 0.000 abstract description 42
206010009657 Clostridium difficile colitis Diseases 0.000 abstract description 35
206010012735 Diarrhoea Diseases 0.000 abstract description 34
208000015181 infectious disease Diseases 0.000 abstract description 26
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 abstract description 18
230000003115 biocidal effect Effects 0.000 abstract description 14
206010037128 Pseudomembranous colitis Diseases 0.000 abstract description 13
239000003242 anti bacterial agent Substances 0.000 abstract description 11
229940088710 antibiotic agent Drugs 0.000 abstract description 11
230000018044 dehydration Effects 0.000 abstract description 11
238000006297 dehydration reaction Methods 0.000 abstract description 11
206010009887 colitis Diseases 0.000 abstract description 8
239000012530 fluid Substances 0.000 abstract description 8
244000005706 microflora Species 0.000 abstract description 4
208000012868 Overgrowth Diseases 0.000 abstract description 2
239000003792 electrolyte Substances 0.000 abstract description 2
230000003090 exacerbative effect Effects 0.000 abstract 1
238000010606 normalization Methods 0.000 abstract 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 51
241000699800 Cricetinae Species 0.000 description 25
238000002474 experimental method Methods 0.000 description 24
241001465754 Metazoa Species 0.000 description 18
241000699670 Mus sp. Species 0.000 description 18
238000011081 inoculation Methods 0.000 description 18
230000004083 survival effect Effects 0.000 description 17
101710084578 Short neurotoxin 1 Proteins 0.000 description 16
101710182532 Toxin a Proteins 0.000 description 16
235000021391 short chain fatty acids Nutrition 0.000 description 16
150000004666 short chain fatty acids Chemical class 0.000 description 16
201000010099 disease Diseases 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
235000005911 diet Nutrition 0.000 description 14
230000037213 diet Effects 0.000 description 14
108010059993 Vancomycin Proteins 0.000 description 13
230000000694 effects Effects 0.000 description 13
229960003165 vancomycin Drugs 0.000 description 13
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 13
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 13
208000005156 Dehydration Diseases 0.000 description 10
239000003053 toxin Substances 0.000 description 10
231100000765 toxin Toxicity 0.000 description 10
108700012359 toxins Proteins 0.000 description 10
210000003608 fece Anatomy 0.000 description 9
238000000034 method Methods 0.000 description 9
150000001720 carbohydrates Chemical class 0.000 description 8
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
230000035611 feeding Effects 0.000 description 8
230000000968 intestinal effect Effects 0.000 description 8
244000215068 Acacia senegal Species 0.000 description 7
229920000084 Gum arabic Polymers 0.000 description 7
239000000205 acacia gum Substances 0.000 description 7
235000010489 acacia gum Nutrition 0.000 description 7
235000014633 carbohydrates Nutrition 0.000 description 7
210000001072 colon Anatomy 0.000 description 7
239000003651 drinking water Substances 0.000 description 7
235000020188 drinking water Nutrition 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
241000186000 Bifidobacterium Species 0.000 description 6
241000699673 Mesocricetus auratus Species 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
244000052769 pathogen Species 0.000 description 6
230000001717 pathogenic effect Effects 0.000 description 6
230000002265 prevention Effects 0.000 description 6
238000005070 sampling Methods 0.000 description 6
208000035473 Communicable disease Diseases 0.000 description 5
101710182223 Toxin B Proteins 0.000 description 5
201000009840 acute diarrhea Diseases 0.000 description 5
238000011553 hamster model Methods 0.000 description 5
230000036541 health Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
208000007976 Ketosis Diseases 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
229960003405 ciprofloxacin Drugs 0.000 description 4
230000000112 colonic effect Effects 0.000 description 4
230000000741 diarrhetic effect Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
229960000282 metronidazole Drugs 0.000 description 4
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
235000016709 nutrition Nutrition 0.000 description 4
230000004044 response Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
235000015872 dietary supplement Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
208000010227 enterocolitis Diseases 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
239000000835 fiber Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
-1 1-ketose Chemical class 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
208000037384 Clostridium Infections Diseases 0.000 description 2
206010054236 Clostridium difficile infection Diseases 0.000 description 2
241000193468 Clostridium perfringens Species 0.000 description 2
101710112752 Cytotoxin Proteins 0.000 description 2
208000014540 Functional gastrointestinal disease Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000001815 ascending colon Anatomy 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
210000004534 cecum Anatomy 0.000 description 2
229960002682 cefoxitin Drugs 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000013480 data collection Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000013401 experimental design Methods 0.000 description 2
230000002550 fecal effect Effects 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
238000003304 gavage Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
230000002688 persistence Effects 0.000 description 2
230000001374 post-anti-biotic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960002181 saccharomyces boulardii Drugs 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
235000021127 solid diet Nutrition 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
229920001221 xylan Polymers 0.000 description 2
150000004823 xylans Chemical class 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
244000003416 Asparagus officinalis Species 0.000 description 1
235000005340 Asparagus officinalis Nutrition 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000017166 Bambusa arundinacea Nutrition 0.000 description 1
235000017491 Bambusa tulda Nutrition 0.000 description 1
241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
208000034598 Caecitis Diseases 0.000 description 1
241001112695 Clostridiales Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
244000019459 Cynara cardunculus Species 0.000 description 1
235000019106 Cynara scolymus Nutrition 0.000 description 1
125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014415 Electrolyte depletion Diseases 0.000 description 1
206010014418 Electrolyte imbalance Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
206010027336 Menstruation delayed Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
240000008790 Musa x paradisiaca Species 0.000 description 1
LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
244000082204 Phyllostachys viridis Species 0.000 description 1
235000015334 Phyllostachys viridis Nutrition 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
235000021536 Sugar beet Nutrition 0.000 description 1
241000223259 Trichoderma Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
208000004387 Typhlitis Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000016520 artichoke thistle Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011425 bamboo Substances 0.000 description 1
235000021015 bananas Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
235000020940 control diet Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
238000012136 culture method Methods 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
239000006160 differential media Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
244000000021 enteric pathogen Species 0.000 description 1
208000037902 enteropathy Diseases 0.000 description 1
231100000249 enterotoxic Toxicity 0.000 description 1
230000002242 enterotoxic effect Effects 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000008029 eradication Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
235000006486 human diet Nutrition 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
206010022694 intestinal perforation Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002584 ketoses Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
210000004767 rumen Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000026775 severe diarrhea Diseases 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000013179 statistical model Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960002197 temoporfin Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
201000002516 toxic megacolon Diseases 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
231100000033 toxigenic Toxicity 0.000 description 1
230000001551 toxigenic effect Effects 0.000 description 1
230000000488 transfructosylating effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hematology (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

NO19974490A 1995-04-05 1997-09-29 Oral rehydreringslösning NO313685B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/417,411 US5733579A (en)	1995-04-05	1995-04-05	Oral rehydration solution containing indigestible oligosaccharides
US08/417,413 US5688777A (en)	1995-04-05	1995-04-05	Inhibition of C. difficile infections by indigestible oligosaccharides
PCT/US1996/004665 WO1996031219A1 (en)	1995-04-05	1996-04-04	Inhibition of c. difficile infections by indigestible oligosaccharides

Publications (3)

Publication Number	Publication Date
NO974490D0 NO974490D0 (no)	1997-09-29
NO974490L NO974490L (no)	1997-09-29
NO313685B1 true NO313685B1 (no)	2002-11-18

Family

ID=27023728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19974490A NO313685B1 (no)	1995-04-05	1997-09-29	Oral rehydreringslösning

Country Status (13)

Country	Link
EP (1)	EP0820292B1 (da)
JP (1)	JPH11503168A (da)
AT (1)	ATE232389T1 (da)
AU (1)	AU704004B2 (da)
CA (1)	CA2217157C (da)
DE (1)	DE69626200T2 (da)
DK (1)	DK0820292T3 (da)
ES (1)	ES2194988T3 (da)
MX (1)	MX9707631A (da)
NO (1)	NO313685B1 (da)
NZ (1)	NZ306712A (da)
PT (1)	PT820292E (da)
WO (1)	WO1996031219A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60031385D1 (de) *	2000-06-28	2006-11-30	B S D Bio Science Dev Snc Di O	Pharmazeutische Zusammensetzungen von Antibiotika und Fruktan-Gemische
EP1243273A1 (en) †	2001-03-22	2002-09-25	Societe Des Produits Nestle S.A.	Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
JP2008514651A (ja) *	2004-09-30	2008-05-08	ユニバーシティー・テクノロジーズ・インターナショナル・インコーポレイテッド	上皮増殖因子（ｅｇｆ）を含んで成る再水和組成物
US20100063002A1 (en) *	2007-03-13	2010-03-11	Bernd Stahl	Method of improving skills with a composition comprising non-digestible saccharide
US20190070204A1 (en) *	2016-03-14	2019-03-07	B Food Science Co., Ltd.	Proliferative agent for faecalibacterium
JP7688866B2 (ja) *	2020-07-14	2025-06-05	物産フードサイエンス株式会社	筋肉量率を増加させる剤および方法、ならびに体脂肪率を減少させる剤および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4902674A (en) *	1987-10-13	1990-02-20	Coors Biotech, Inc.	Method for inhibiting the growth of salmonella
NZ232346A (en) *	1989-02-07	1992-03-26	Duphar Int Res	Effervescent oral rehydration solution comprising saccharides, amino acids and bicarbonate salts
US5397786A (en) *	1993-01-08	1995-03-14	Simone; Charles B.	Rehydration drink

1996
- 1996-04-04 AT AT96912568T patent/ATE232389T1/de not_active IP Right Cessation
- 1996-04-04 MX MX9707631A patent/MX9707631A/es not_active IP Right Cessation
- 1996-04-04 EP EP96912568A patent/EP0820292B1/en not_active Expired - Lifetime
- 1996-04-04 JP JP8530480A patent/JPH11503168A/ja not_active Ceased
- 1996-04-04 AU AU55342/96A patent/AU704004B2/en not_active Ceased
- 1996-04-04 ES ES96912568T patent/ES2194988T3/es not_active Expired - Lifetime
- 1996-04-04 WO PCT/US1996/004665 patent/WO1996031219A1/en not_active Ceased
- 1996-04-04 DE DE69626200T patent/DE69626200T2/de not_active Expired - Lifetime
- 1996-04-04 CA CA002217157A patent/CA2217157C/en not_active Expired - Fee Related
- 1996-04-04 PT PT96912568T patent/PT820292E/pt unknown
- 1996-04-04 DK DK96912568T patent/DK0820292T3/da active
- 1996-04-04 NZ NZ306712A patent/NZ306712A/en unknown
1997
- 1997-09-29 NO NO19974490A patent/NO313685B1/no unknown

Also Published As

Publication number	Publication date
CA2217157C (en)	2002-07-30
MX9707631A (es)	1998-04-30
DE69626200T2 (de)	2003-12-18
JPH11503168A (ja)	1999-03-23
HK1008492A1 (en)	1999-05-14
EP0820292B1 (en)	2003-02-12
EP0820292A1 (en)	1998-01-28
NO974490D0 (no)	1997-09-29
WO1996031219A1 (en)	1996-10-10
ATE232389T1 (de)	2003-02-15
CA2217157A1 (en)	1996-10-10
AU5534296A (en)	1996-10-23
PT820292E (pt)	2003-06-30
DK0820292T3 (da)	2003-05-19
ES2194988T3 (es)	2003-12-01
DE69626200D1 (de)	2003-03-20
NO974490L (no)	1997-09-29
AU704004B2 (en)	1999-04-01
NZ306712A (en)	1999-10-28

Publication	Publication Date	Title
US5733579A (en)	1998-03-31	Oral rehydration solution containing indigestible oligosaccharides
Campbell et al.	1997	Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats
Dittoe et al.	2018	Organic acids and potential for modifying the avian gastrointestinal tract and reducing pathogens and disease
Gonzales‐Siles et al.	2016	The different ecological niches of enterotoxigenic E scherichia coli
DK1644482T4 (da)	2014-12-15	Hidtil ukendt galactooligosaccharidpræparat og fremstillingen deraf
CN103491969A (zh)	2014-01-01	恢复和重建肠道微生物群的合生素组合物
JP2007518693A (ja)	2007-07-12	安定な液体プロバイオティクス組成物、その調製および適用
PT986314E (pt)	2008-12-30	Bactéria láctica probiótica para tratar infecções bacterianas associadas à sids
US12558386B2 (en)	2026-02-24	Methods and compositions to modulate antibiotic resistance and gastrointestinal microbiota
Wrigley	2004	Inhibition of Clostridium perfringens sporulation by Bacteroides fragilis and short-chain fatty acids
KR0145553B1 (ko)	1998-08-17	클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
Surawicz	2005	Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?
AU2020257267A1 (en)	2021-11-18	Compositions including novel microbes with enhanced persistence, synergistic combinations of novel microbes and prebiotics, and methods for the isolation of such microbes
NO313685B1 (no)	2002-11-18	Oral rehydreringslösning
RU2401111C1 (ru)	2010-10-10	Препарат для лечения сальмонеллеза у молодняка сельскохозяйственных животных
CN100434510C (zh)	2008-11-19	新的半乳糖寡糖组合物及其制备
US5688777A (en)	1997-11-18	Inhibition of C. difficile infections by indigestible oligosaccharides
WO2011043695A1 (ru)	2011-04-14	Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
Moore et al.	2022	Galacto‐Oligosaccharide Supplementation Modulates Pathogen‐Commensal Competition between Streptococcus agalactiae and Streptococcus salivarius
HK1008492B (en)	2003-11-21	Inhibition of c. difficile infections by indigestible oligosaccharides
MXPA97007631A (en)		Inhibition of infections by c. difficilemediante oligosacaridos indigestib
Skariyachan et al.	2016	Evolution and prevalence of multidrug resistance among foodborne pathogens
Hendlin et al.	1977	Effect of fosfomycin on the fecal microflora of man
Kiarie	2008	Dietary means for enhanced gastrointestinal health and function in weaned pigs: an evaluation of carbohydrase enzymes targeting non-starch polysaccharides
AL-musawy et al.	2023	Effect of adding Zeolite to the diet in health status of broiler infected with pathogenic E. coli O157: H7